Beyond the positive selection bias of the patients who tolerate the drug, the other possible explanations for the decrease in infection risk with ongoing TNF antagonist therapy may include decreased use of corticosteroids and better control of the RA disease process that reduces disease-associated alterations in natural immunity [18,19]. This evidence concerns the gene TNF and infection.